Home / Pharmaceutical company intelligence
SAMI Pharmaceuticals Pvt. Ltd. logo
Pharmaceutical company intelligence

SAMI Pharmaceuticals Pvt. Ltd.

Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.

Private pharmaceutical manufacturer · Karachi · Pakistan

Karachi-based pharmaceutical manufacturer and marketer of branded generic medicines across major therapeutic categories.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation25 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check25 Sep 2026Latest source-check date across this published portfolio
Latest effective price date4 Aug 2026Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
SAMI Pharmaceuticals (Pvt.) Ltd.
Company type
Private pharmaceutical manufacturer
Address
34-C, Block-6, P.E.C.H.S., Karachi-75350, Pakistan · 75350
Phone
+92 21 34527490-92
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000072 Sami Pharmaceuticals (Pvt) Ltd. · Sindh
Formulation 000731 Sami Pharmaceuticals (Pvt) Ltd. · Sindh
Semi Basic Manufacture 000907 Sami Pharmaceuticals (Pvt) Ltd. · Sindh
Formulation 000938 Sami Pharmaceuticals (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000072 192 linked products · source seen 25 Sep 2026 View source ↗
DML 000938 3 linked products · source seen 25 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx203public portfolio records represented
REG152unique registrations represented
IDX99indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR194current validated price records
G64generic molecules in indexed catalogue
DF8dosage-form groups
TA11therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage96%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixSAMI Pharmaceuticals Pvt. Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/sami-pharmaceuticals-pvt-ltdGenerated 25 Sep 2026Anti-infectives99 · 51%Cardiovascular24 · 12%Endocrine & metabolic18 · 9%Vitamins, minerals & nutrition10 · 5%Oncology & immunology9 · 5%Hematology & thrombosis9 · 5%Gastrointestinal & hepatology9 · 5%Other therapeutic areas17 · 9%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioSAMI Pharmaceuticals Pvt. Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/sami-pharmaceuticals-pvt-ltdGenerated 25 Sep 2026195presentationsTablet97 · 50%Injection49 · 25%Capsule16 · 8%Suspension16 · 8%Infusion12 · 6%Solution3 · 2%Other forms2 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionSAMI Pharmaceuticals Pvt. Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/sami-pharmaceuticals-pvt-ltdGenerated 25 Sep 2026180comparable productsBelow peer median14 · 8%Near peer median60 · 33%Above peer median106 · 59%Company median price position+7.3%Lowest-price equivalents10Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsSAMI Pharmaceuticals Pvt. Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/sami-pharmaceuticals-pvt-ltdGenerated 25 Sep 2026M/s. Genix Pharma (Pvt) Ltd.41 shared64% overlapMacter International Limited41 shared64% overlapHIGH-Q Pharmaceuticals39 shared61% overlapTABROS PHARMA (PVT). LTD.39 shared61% overlapNabiqasim Industries (Pvt) Ltd.,38 shared59% overlapBosch Pharmaceuticals (Pvt) Ltd.38 shared59% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives99 products · 51%
Cardiovascular24 products · 12%
Endocrine & metabolic18 products · 9%
Vitamins, minerals & nutrition10 products · 5%
Oncology & immunology9 products · 5%
Hematology & thrombosis9 products · 5%
Gastrointestinal & hepatology9 products · 5%
Pain & musculoskeletal9 products · 5%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antivirals20 products · 10%
Antidiabetic medicines17 products · 9%
Third-generation cephalosporins15 products · 8%
Calcium-channel blockers15 products · 8%
Antimalarials12 products · 6%
Macrolide antibacterials12 products · 6%
Fluoroquinolone antibacterials12 products · 6%
Vitamins / minerals / hematinics10 products · 5%
Formulation footprint

Dosage forms

Tablet97 products
Injection49 products
Capsule16 products
Suspension16 products
Infusion12 products
Solution3 products
Drops1 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 RYBIORibavirin 11presentations 200 mg, 400 mg, 500 mg, 600 mg · Tablet, Capsule #2 TELARB-PlusTelmisartan + Amlodipine 11presentations 40 mg + 10 mg, 40 mg + 5 mg, 80 mg + 10 mg, 80 mg + 5 mg · Tablet #3 EMPOLIEmpagliflozin 10presentations 10 mg, 25 mg · Tablet #4 GrasilAmikacin 7presentations 100 mg, 25 mg, 25 mg/1 mL, 250 mg · Injection #5 NOVIDATCiprofloxacin 7presentations 125 mg/5 mL, 200 mg/100 mL, 250 mg, 250 mg/5 mL · Suspension, Infusion, Tablet #6 ARILIOTacrolimus 6presentations 0.5 mg, 1 mg, 5 mg · Capsule
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median148% of comparable products
Near market median60within ±5% of median
Above market median10659% of comparable products
Lowest-price equivalents10ties included
Company median price position +7.3% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Fungone 100 mg/50 mLFluconazole · IV infusion · 50ml PKR 3.15/mL-70.5% vs market median ONATO 10 mgAmlodipine · Tablet · 3x10's PKR 10.22/tablet-42.5% vs market median ONATO 10 mgAmlodipine · Tablet · 20's PKR 10.22/tablet-42.5% vs market median CARICEF 100 mg/5 mLCefixime · Suspension · 60 ml PKR 6.82/mL-35.1% vs market median OLMETHATE 1 MIUColistimethate sodium · Injection · 1's PKR 1,108.52/vial/unit-33.2% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 41shared generics Macter International Limited256 products · 93 generics 41shared generics HIGH-Q Pharmaceuticals215 products · 61 generics 39shared generics TABROS PHARMA (PVT). LTD.179 products · 65 generics 39shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 38shared generics Bosch Pharmaceuticals (Pvt) Ltd.258 products · 74 generics 38shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers145Distinct registrations among indexed, published, presentation-validated products only
Verified price observations195
Products with a verified price195
Products with multiple price observations0
Source records with multiple versions188
Latest portfolio source check25 Sep 2026
Latest effective price date4 Aug 2026
Latest source observation25 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

152 unique registration(s) · 99 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Arcenate Artesunate 30 mg Injection 1's 100927 PKR 148.71 PKR 148.71/vial/unit Near median
Arcenate Artesunate 60 mg Injection 1's 100928 PKR 247.84 PKR 247.84/vial/unit Near median
Arcenate Artesunate 120 mg Injection 1's 100929 PKR 413.07 PKR 413.07/vial/unit Near median
ARCEVA Artemether + Lumefantrine 20 mg + 120 mg Tablet 16's 053225 PKR 660.92 PKR 41.31/tablet 5% above median
ARCEVA Artemether + Lumefantrine 40 mg + 240 mg Tablet 8's 053226 PKR 545.26 PKR 68.16/tablet 6% above median
ARCEVA Artemether + Lumefantrine 80 mg + 480 mg Tablet 6's 058381 PKR 681.55 PKR 113.59/tablet Near median
ARCEVA Artemether 80 mg/mL Injection 6 x 1 ml 085601 PKR 1,239.23 PKR 206.54/mL 11% above median
ARCEVA Artemether 80 mg/mL Injection 5 x 1 ml 085601 PKR 977.38 PKR 195.48/mL Near median
ARCEVA 20 Artemether + Lumefantrine 20 mg + 120 mg Tablet 16's 053225 PKR 660.92 PKR 41.31/tablet 5% above median
AZITMA Azithromycin 250 mg Tablet 6's 074899 PKR 314.07 PKR 52.35/tablet 12% above median
AZITMA Azithromycin 250 mg Tablet 12's 074899 PKR 615.58 PKR 51.30/tablet 9% above median
AZITMA Azithromycin 500 mg Tablet 6's 074900 PKR 575.83 PKR 95.97/tablet 13% above median
AZITMA Azithromycin 200 mg/5 mL Suspension 30ml 074902 PKR 677.57 PKR 22.59/mL Near median
AZITMA Azithromycin 200 mg/5 mL Suspension 15ml 074902 PKR 345.48 PKR 23.03/mL 6% above median
BELIC Entecavir 1 mg Tablet 30's 085603 PKR 22,237.81 PKR 741.26/tablet 28% above median
BELIC Entecavir 0.05 mg/mL Oral solution 120ml 088232 PKR 5,186.31 PKR 43.22/mL Near median
CARICEF Cefixime 100 mg/5 mL Suspension 60 ml 022415 PKR 408.93 PKR 6.82/mL 35% below median
CARICEF Cefixime 100 mg/5 mL Suspension 30 ml 022415 PKR 365.33 PKR 12.18/mL 16% above median
CARICEF Cefixime 400 mg Capsule 5's 022416 PKR 654.67 PKR 130.93/capsule 16% above median
CARICEF Cefixime 200 mg/5 mL Suspension 30 ml 044340 PKR 447.08 PKR 14.90/mL 12% above median
CARICEF Cefixime 200 mg Tablet 10's 070790 PKR 648.51 PKR 64.85/tablet Near median
Cynfo Fosfomycin 1 g Powder for IV infusion 1's 089069 PKR 82.16 PKR 82.16/vial/unit No comparator
Cynfo Fosfomycin 1 g Solution for infusion 1's 089069 PKR 82.16 PKR 82.16/vial/unit No comparator
DEVAZO Daclatasvir 30 mg Tablet 28s 084766 PKR 5,710.84 PKR 203.96/tablet 6% above median
DEVAZO Daclatasvir 60 mg Tablet 28s 084767 PKR 9,344.25 PKR 333.72/tablet Near median
ECASIL Linezolid 600 mg Tablet 12's 066904 PKR 5,351.96 PKR 446.00/tablet 13% above median
ECASIL Linezolid 400 mg Tablet 12's 067162 PKR 3,057.07 PKR 254.76/tablet 11% above median
ECASIL Linezolid 200 mg/100 mL IV infusion 100ml Vial 067516 PKR 724.49 PKR 7.24/mL Near median
ECASIL Linezolid 600 mg/300 mL IV infusion 300ml Vial 067518 PKR 1,256.33 PKR 4.19/mL 9% above median
ECASIL Linezolid 100 mg/5 mL Suspension 60ml 076058 PKR 732.85 PKR 12.21/mL 11% above median
EFFIFLOX Levofloxacin 250 mg Tablet 10's 037709 PKR 516.30 PKR 51.63/tablet 8% above median
EFFIFLOX Levofloxacin 500 mg Tablet 10's 037710 PKR 859.18 PKR 85.92/tablet 9% above median
Fungone Fluconazole 150 mg Capsule 1's 044273 PKR 387.72 PKR 387.72/capsule 48% above median
Fungone Fluconazole 50 mg Capsule 7's 080661 PKR 929.38 PKR 132.77/capsule 8% above median
Fungone Fluconazole 100 mg/50 mL IV infusion 50ml 086777 PKR 157.60 PKR 3.15/mL 70% below median
Fungone Fluconazole 50 mg/5 mL Suspension 35ml 086969 PKR 418.89 PKR 11.97/mL Near median
Grasil Amikacin 250 mg Injection 2 ml 013530 PKR 341.19 PKR 170.60/mL 160% above median
Grasil Amikacin 500 mg Injection 2 ml 014251 PKR 483.16 PKR 241.58/mL 99% above median
Grasil Amikacin 100 mg Injection 2 ml 019704 PKR 169.15 PKR 84.58/mL 100% above median
Grasil Amikacin 25 mg/1 mL Injection 1 ml 047143 PKR 46.18 PKR 46.18/mL No comparator
Grasil Amikacin 25 mg Injection 1 ml 047143 PKR 46.18 PKR 46.18/mL 12% above median
Grasil Amikacin 50 mg/1 mL Injection 1 ml 047144 PKR 57.64 PKR 57.64/mL No comparator
Grasil Amikacin 50 mg Injection 1 ml 047144 PKR 57.64 PKR 57.64/mL 29% above median
KLINT Metronidazole 400 mg Tablet 150's 014422 PKR 556.25 PKR 3.71/tablet 25% above median
KLINT Metronidazole (Benzoate) 200 mg/5 mL Suspension 90ml 014423 PKR 99.14 PKR 1.10/mL 12% above median
KLINT Injection1 Metronidazole 5 mg Injection 100ml Vial 011431 PKR 189.93 PKR 1.90/mL No comparator
Mdestiv Remdesivir 100 mg Lyophilized powder for IV infusion 1's 103176 PKR 2,629.39 PKR 2,629.39/vial/unit No comparator
Mefloq Mefloquine 250 mg Tablet 10's 039282 PKR 475.03 PKR 47.50/tablet 12% above median
MOFEST Moxifloxacin 400 mg Tablet 5's 050745 PKR 994.60 PKR 198.92/tablet 9% above median
NIVADOR Ceftazidime 250 mg Injection Vial 037548 PKR 167.86 PKR 167.86/vial/unit Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). SAMI Pharmaceuticals Pvt. Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 25, 2026, from https://medinfobase.com/company/sami-pharmaceuticals-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.